Revisiting the role of TEG-PM in stroke prevention by drug selection for mono-antiplatelet medication following dual-antiplatelet treatment
CONCLUSION: The TEG-PM could be a tangible preprocessing in drug selection for MAPT following DAPT in patients with minor strokes or TIAs, especially for those with non-stented ICASs.PMID:38295427 (Source: Neuroendocrinology Letters)
Source: Neuroendocrinology Letters - January 31, 2024 Category: Endocrinology Authors: Lei Yan Wenzhao Liang Bingyang Zhao Zhongyu Zhao Kai Zhang Lingling Wang Jing Mang Source Type: research
Identifying causative medications for agranulocytosis: A case report of an older adult with cerebral infarction
We present the case of a 93-year-old man who was admitted for the treatment of cerebrovascular events. The patient was initially prescribed dual antiplatelet therapy with aspirin and clopidogrel along with lansoprazole, Hange-koboku-toh, and elobixibat. On day 36 after admission, the patient was found to have developed agranulocytosis. To improve his cerebrovascular prognosis, we first discontinued medications other than the anticoagulant medicines and initiated filgrastim. We discontinued clopidogrel 9 days after the discontinuation of the other medicines considering his low white blood cell count. One day after the di...
Source: Clinical Case Reports - January 29, 2024 Category: General Medicine Authors: Yuuri Kurokawa,
Ayako Watanabe,
Yuka Kashiwabara,
Saori Fukuda,
Shohei Nomoto,
Ayako Kuriki,
Kenji Momo Tags: CASE REPORT Source Type: research
Prevalence of CYP2C19*2 and CYP2C19*3 Allelic Variants and Clopidogrel Use in Patients with Cardiovascular Disease in Trinidad & amp; Tobago
ConclusionsA large proportion of Trinidadian patients with CVD who are prescribed or may be prescribed clopidogrel carry genetic variants associated with clopidogrel resistance. These results emphasize the clinical need for further investigation into whetherCYP2C19*2 genotype should guide clopidogrel use for the cardiovascular disease population in Trinidad& Tobago.A slide deck is available for this article. (Source: Cardiology and Therapy)
Source: Cardiology and Therapy - January 29, 2024 Category: Cardiology Source Type: research
Effects of antiplatelet therapy on menstrual blood loss in reproductive-aged women: a systematic review
CONCLUSION: There is lack of high-quality data on the effects of antiplatelet therapy on menstrual bleeding. Aspirin may increase menstrual blood loss, at least in a minority of women, whereas the effects of P2Y12 inhibitors are unknown.PMID:38268520 | PMC:PMC10805676 | DOI:10.1016/j.rpth.2023.102295 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - January 25, 2024 Category: Hematology Authors: Eva K Kempers Johanna A van der Zande Paula M Janssen J érôme M J Cornette Jolien W Roos-Hesselink Marieke J H A Kruip Source Type: research
Comment on: “Comparison of Clinical Outcomes Between Ticagrelor and Clopidogrel in East-Asian Patients with Acute Coronary Syndrome: Large Cohort Study”
(Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - January 25, 2024 Category: Cardiology Source Type: research
